Merida Biosciences, a biotechnology company, has launched with $121 million in Series A financing. The financing was co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, joined by GV and Perceptive Xontogeny Venture Funds (PXV Funds). Merida has developed a novel platform to precisely target the pathogenic antibodies that underpin a wide array of autoimmune and allergic diseases. The company is developing antibody-like therapeutics with the potential to drive deep and d...